VYNE Therapeutics (VYNE) Expected to Announce Earnings on Thursday

Posted by George Bondi on Aug 11th, 2026

VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) is expected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.20 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($4.00) EPS for the quarter, beating the consensus estimate of ($9.00) by $5.00. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

VYNE Therapeutics Stock Performance

Shares of NASDAQ VYNE opened at $28.32 on Tuesday. VYNE Therapeutics has a fifty-two week low of $14.03 and a fifty-two week high of $79.75. The company has a market cap of $18.98 million, a PE ratio of -74.54 and a beta of 2.00. The business has a 50-day simple moving average of $32.92 and a two-hundred day simple moving average of $31.49.

VYNE Therapeutics Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were issued a $19.00 dividend.

Institutional Investors Weigh In On VYNE Therapeutics

Large investors have recently bought and sold shares of the company. KVP Capital Advisors LP acquired a new stake in shares of VYNE Therapeutics in the fourth quarter valued at approximately $290,000. Anson Funds Management LP acquired a new position in VYNE Therapeutics during the fourth quarter worth $739,000. Nantahala Capital Management LLC purchased a new stake in VYNE Therapeutics in the 4th quarter valued at $580,000. Adage Capital Partners GP L.L.C. grew its holdings in VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after buying an additional 300,000 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of VYNE Therapeutics in the 2nd quarter worth $206,000. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Get Our Latest Research Report on VYNE Therapeutics

About VYNE Therapeutics

(Get Free Report)

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.